Mars Bioimaging and MediLumine announce a partnership to develop applications for small animal imaging and jointly announce the success of a pilot study using MediLumine’s contrast agents and the MARS color x-ray imaging system.
In this study, the MARS scanner simultaneously identified and quantified three MediLumine contrast agents, Fenestra VC, Mvivo Au, and Mvivo BIS in a phantom with vials of the contrast agents. The different contrast agents can be visualized in 3D and assigned different colors based on ability of MARS technology to detect differences in attenuation slopes and k-edge jumps.
The MARS scanner enables simultaneous visualization and quantification of contrast agents in vivo.
MediLumine and MARS will now work jointly on applications and related technical resources to facilitate small animal imaging research with contrast enhanced color x-ray imaging.
I'm really excited about this partnership as it combines the power of MARS quantitative imaging with the MediLumine's functional contrast agents. The combination of the two technologies greatly increases the opportunity for novel molecular imaging for pre-clinical researchers.
Working with MARS Bioimaging unlocks the potential of color x-ray imaging by providing a means to visualize disease in ways not yet imagined. Contrast enhanced color x-ray imaging will become a powerful tool in understanding human diseases and advancing drug discovery programs internationally.
MediLumine is committed to providing high quality instruments, reagents and accessories to support preclinical imaging programs in the life sciences. MediLumine’s PRISM™ series of in vivo imaging systems are designed for preclinical monitoring of physiological changes in living systems for therapeutic discovery research in universities and pharmaceutical companies. MediLumine’s Fenestra® and Mvivo™ contrast agents for micro-CT Imaging provide image enhancement for various applications allowing scientists to monitor progression of functional liver diseases, quantify tumor burdens, track cells in vivo and perform preclinical angiography. For more information refer to www.medilumine.com
MARS Bioimaging is a New Zealand-based manufacturer of high-resolution color x-ray systems for preclinical and point-of-care imaging. They offer quantitative color x-ray imaging solutions for researchers, complete with 2D/3D visualisation and advanced image analysis tools. For more information refer to www.marsbioimaging.com
A recent study offers insights into a novel approach to cardiac repair by inhibiting ENPP1, an enzyme critical to regulating extracellular nucleotide metabolism. MediLumine’s Fenestra
Recent advancements in high-resolution micro CT imaging have opened new doors for researchers, enabling them to explore microvascular structures in unprecedented detail. Unlocking the Power
Copyright © 2024 · MediLumine, Inc · All Rights Reserved
